factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 246-249 | 246-249 | T23 | for | TREATS | 246 | 249 | preserve | 231-245 | 231-245 | T16 | fundoplication | TherapeuticOrPreventiveProcedure | 231 | 245 | preserve | 284-314 | 306-314 | T18 | delayed gastric emptying | Finding | 284 | 314 | A12 | PURPOSE: Although several centers often perform gastric emptying procedures (GEP) together with fundoplication for gastroesophageal reflux (GER) and delayed gastric emptying (DGE), the benefit of GEP is controversial. | 129-358 | 129 | 358 | PURPOSE: Although several centers often perform gastric emptying procedures (GEP) together with @SUBJECT$ @PREDICAT$ gastroesophageal reflux (GER) and @OBJECT$ (DGE), the benefit of GEP is controversial. |
Fact | preserve | 246-249 | 246-249 | T23 | for | TREATS | 246 | 249 | preserve | 231-245 | 231-245 | T16 | fundoplication | TherapeuticOrPreventiveProcedure | 231 | 245 | preserve | 250-273 | 267-273 | T17 | gastroesophageal reflux | DiseaseOrSyndrome | 250 | 273 | A13 | PURPOSE: Although several centers often perform gastric emptying procedures (GEP) together with fundoplication for gastroesophageal reflux (GER) and delayed gastric emptying (DGE), the benefit of GEP is controversial. | 129-358 | 129 | 358 | PURPOSE: Although several centers often perform gastric emptying procedures (GEP) together with @SUBJECT$ @PREDICAT$ @OBJECT$ (GER) and delayed gastric emptying (DGE), the benefit of GEP is controversial. |
Uncommitted | preserve | 442-446 | 442-446 | T51 | role | ASSOCIATED_WITH | 442 | 446 | preserve | 450-454 | 450-454 | T22 | iNOS | AminoAcidPeptideOrProtein | 450 | 454 | preserve | 462-481 | 471-481 | T23 | ischemic myocardium | DiseaseOrSyndrome | 462 | 481 | A3 | To examine the role of iNOS in the ischemic myocardium, we studied: 1) the time course of expression of iNOS mRNA after myocardial infarction (MI) in male Sprague-Dawley rat hearts and expression of iNOS protein in the infarcted region; 2) whether hypoxia in vitro is a potential mediator of the induction of iNOS mRNA; and 3) whether inhibition of iNOS by two different selective inhibitors (aminoguanidine and S-methylisothiourea sulfate) in vivo influences infarct size. | 421-930 | 421 | 930 | To examine the @PREDICAT$ of @SUBJECT$ in the @OBJECT$ , we studied: 1) the time course of expression of iNOS mRNA after myocardial infarction (MI) in male Sprague-Dawley rat hearts and expression of iNOS protein in the infarcted region; 2) whether hypoxia in vitro is a potential mediator of the induction of iNOS mRNA; and 3) whether inhibition of iNOS by two different selective inhibitors (aminoguanidine and S-methylisothiourea sulfate) in vivo influences infarct size. |
Fact | preserve | 957-964 | 957-964 | T63 | induced | CAUSES | 957 | 964 | preserve | 968-976 | 968-976 | T55 | ligation | TherapeuticOrPreventiveProcedure | 968 | 976 | preserve | 931-952 | 942-952 | T54 | Myocardial infarction | DiseaseOrSyndrome | 931 | 952 | A5 | Myocardial infarction was induced by ligation of the left anterior descending coronary artery (LAD), and tissue was collected at selected times thereafter from both ligated and sham-operated rats. | 931-1139 | 931 | 1,139 | @OBJECT$ was @PREDICAT$ by @SUBJECT$ of the left anterior descending coronary artery (LAD), and tissue was collected at selected times thereafter from both ligated and sham-operated rats. |
Fact | preserve | 147-158 | 147-158 | T11 | upregulated | STIMULATES | 147 | 158 | preserve | 182-192 | 182-192 | T7 | endotoxins | Carbohydrate | 182 | 192 | preserve | 97-128 | 120-128 | T4 | inducible nitric oxide synthase | AminoAcidPeptideOrProtein | 97 | 128 | A7 | The inducible nitric oxide synthase isoform (iNOS) is upregulated by cytokines and endotoxins in many types of cells, including cardiac myocytes. | 93-244 | 93 | 244 | The @OBJECT$ isoform (iNOS) is @PREDICAT$ by cytokines and @SUBJECT$ in many types of cells, including cardiac myocytes. |
Fact | preserve | 147-158 | 147-158 | T11 | upregulated | STIMULATES | 147 | 158 | preserve | 162-171 | 162-171 | T6 | cytokines | AminoAcidPeptideOrProtein | 162 | 171 | preserve | 97-128 | 120-128 | T4 | inducible nitric oxide synthase | AminoAcidPeptideOrProtein | 97 | 128 | A8 | The inducible nitric oxide synthase isoform (iNOS) is upregulated by cytokines and endotoxins in many types of cells, including cardiac myocytes. | 93-244 | 93 | 244 | The @OBJECT$ isoform (iNOS) is @PREDICAT$ by @SUBJECT$ and endotoxins in many types of cells, including cardiac myocytes. |
Fact | preserve | 269-276 | 269-276 | T20 | induced | STIMULATES | 269 | 276 | preserve | 280-289 | 280-289 | T14 | cytokines | AminoAcidPeptideOrProtein | 280 | 289 | preserve | 245-257 | 252-257 | T13 | Nitric oxide | BiologicallyActiveSubstance | 245 | 257 | A9 | Nitric oxide (NO) induced by cytokines can be cytotoxic, and has been implicated in the pathophysiology of myocardial infarction, cardiomyopathy, and septic shock. | 245-420 | 245 | 420 | @OBJECT$ (NO) @PREDICAT$ by @SUBJECT$ can be cytotoxic, and has been implicated in the pathophysiology of myocardial infarction, cardiomyopathy, and septic shock. |
Fact | preserve | 2029-2036 | 2029-2036 | T135 | derived | CONVERTS_TO | 2,029 | 2,036 | preserve | 2046-2050 | 2046-2050 | T124 | iNOS | AminoAcidPeptideOrProtein | 2,046 | 2,050 | preserve | 2026-2028 | 2026-2028 | T123 | NO | BiologicallyActiveSubstance | 2,026 | 2,028 | A10 | These data suggest that NO derived from the iNOS isoform contributes to some of the myocardial injury following MI, possibly by causing myocardial cell death in areas bordering the ischemic region of the heart. | 1996-2224 | 1,996 | 2,224 | These data suggest that @OBJECT$ @PREDICAT$ from the @SUBJECT$ isoform contributes to some of the myocardial injury following MI, possibly by causing myocardial cell death in areas bordering the ischemic region of the heart. |
Fact | preserve | 594-619 | 613-619 | T52 | Sprague-Dawley rat hearts | PART_OF | 594 | 619 | preserve | 613-619 | 613-619 | T30 | hearts | BodyPartOrganOrOrganComponent | 613 | 619 | preserve | 594-612 | 609-612 | T29 | Sprague-Dawley rat | Mammal | 594 | 612 | A11 | To examine the role of iNOS in the ischemic myocardium, we studied: 1) the time course of expression of iNOS mRNA after myocardial infarction (MI) in male Sprague-Dawley rat hearts and expression of iNOS protein in the infarcted region; 2) whether hypoxia in vitro is a potential mediator of the induction of iNOS mRNA; and 3) whether inhibition of iNOS by two different selective inhibitors (aminoguanidine and S-methylisothiourea sulfate) in vivo influences infarct size. | 421-930 | 421 | 930 | To examine the role of iNOS in the ischemic myocardium, we studied: 1) the time course of expression of iNOS mRNA after myocardial infarction (MI) in male @OBJECT$ @PREDICAT$ @SUBJECT$ and expression of iNOS protein in the infarcted region; 2) whether hypoxia in vitro is a potential mediator of the induction of iNOS mRNA; and 3) whether inhibition of iNOS by two different selective inhibitors (aminoguanidine and S-methylisothiourea sulfate) in vivo influences infarct size. |
Fact | preserve | 1041-1051 | 1047-1051 | T93 | obese rats | PROCESS_OF | 1,041 | 1,051 | preserve | 1041-1046 | 1041-1046 | T83 | obese | DiseaseOrSyndrome | 1,041 | 1,046 | preserve | 1047-1051 | 1047-1051 | T84 | rats | Mammal | 1,047 | 1,051 | A1 | The fact that estrone oleate had no effect on the leptin levels or expression in obese rats, in contrast with the marked inhibition observed in the lean suggests that the functionality of the leptin receptor is essential for estrone oleate inhibition of the ob gene. | 954-1244 | 954 | 1,244 | The fact that estrone oleate had no effect on the leptin levels or expression in @SUBJECT$ @PREDICAT$ @OBJECT$ , in contrast with the marked inhibition observed in the lean suggests that the functionality of the leptin receptor is essential for estrone oleate inhibition of the ob gene. |
Fact | preserve | 627-638 | 634-638 | T54 | Plasma ACTH | LOCATION_OF | 627 | 638 | preserve | 627-633 | 627-633 | T48 | Plasma | BodySubstance | 627 | 633 | preserve | 634-638 | 634-638 | T49 | ACTH | AminoAcidPeptideOrProtein | 634 | 638 | A5 | Plasma ACTH and corticosterone increased to a maximum at the end of the experiment. | 627-716 | 627 | 716 | @SUBJECT$ @PREDICAT$ @OBJECT$ and corticosterone increased to a maximum at the end of the experiment. |
Counterfact | preserve | 1628-1636 | 1628-1636 | T119 | mediated | AFFECTS | 1,628 | 1,636 | preserve | 1646-1652 | 1646-1652 | T115 | leptin | AminoAcidPeptideOrProtein | 1,646 | 1,652 | preserve | 1596-1604 | 1596-1604 | T113 | appetite | OrganismFunction | 1,596 | 1,604 | A6 | The slimming effect of estrone oleate is, thus, not directly dependent on leptin, since both normoleptinemic and hyperleptinemic animals lose fat following treatment nor are the effects on appetite and energy expenditure mediated by leptin. | 1389-1653 | 1,389 | 1,653 | The slimming effect of estrone oleate is, thus, not directly dependent on leptin, since both normoleptinemic and hyperleptinemic animals lose fat following treatment nor are the effects on @OBJECT$ and energy expenditure @PREDICAT$ by @SUBJECT$ . |
Counterfact | preserve | 1628-1636 | 1628-1636 | T119 | mediated | AFFECTS | 1,628 | 1,636 | preserve | 1646-1652 | 1646-1652 | T115 | leptin | AminoAcidPeptideOrProtein | 1,646 | 1,652 | preserve | 1609-1627 | 1616-1627 | T114 | energy expenditure | PhysiologicFunction | 1,609 | 1,627 | A15 | The slimming effect of estrone oleate is, thus, not directly dependent on leptin, since both normoleptinemic and hyperleptinemic animals lose fat following treatment nor are the effects on appetite and energy expenditure mediated by leptin. | 1389-1653 | 1,389 | 1,653 | The slimming effect of estrone oleate is, thus, not directly dependent on leptin, since both normoleptinemic and hyperleptinemic animals lose fat following treatment nor are the effects on appetite and @OBJECT$ @PREDICAT$ by @SUBJECT$ . |
Counterfact | preserve | 1456-1465 | 1456-1465 | T116 | dependent | STIMULATES | 1,456 | 1,465 | preserve | 1469-1475 | 1469-1475 | T108 | leptin | AminoAcidPeptideOrProtein | 1,469 | 1,475 | preserve | 1426-1432 | 1426-1432 | T106 | oleate | Lipid | 1,426 | 1,432 | A16 | The slimming effect of estrone oleate is, thus, not directly dependent on leptin, since both normoleptinemic and hyperleptinemic animals lose fat following treatment nor are the effects on appetite and energy expenditure mediated by leptin. | 1389-1653 | 1,389 | 1,653 | The slimming effect of estrone @OBJECT$ is, thus, not directly @PREDICAT$ on @SUBJECT$ , since both normoleptinemic and hyperleptinemic animals lose fat following treatment nor are the effects on appetite and energy expenditure mediated by leptin. |
Fact | preserve | 790-803 | 797-803 | T67 | plasma leptin | LOCATION_OF | 790 | 803 | preserve | 790-796 | 790-796 | T61 | plasma | BodySubstance | 790 | 796 | preserve | 797-803 | 797-803 | T62 | leptin | AminoAcidPeptideOrProtein | 797 | 803 | A17 | The expression of the ob gene in adipose tissue was unchanged, and plasma leptin levels were also unchanged by treatment. | 717-850 | 717 | 850 | The expression of the ob gene in adipose tissue was unchanged, and @SUBJECT$ @PREDICAT$ @OBJECT$ levels were also unchanged by treatment. |
Fact | preserve | 21-25 | 21-25 | T12 | with | USES | 21 | 25 | preserve | 11-20 | 11-20 | T2 | treatment | TherapeuticOrPreventiveProcedure | 11 | 20 | preserve | 34-40 | 34-40 | T4 | oleate | BiologicallyActiveSubstance | 34 | 40 | A18 | Short-term treatment with estrone oleate in liposomes (Merlin-2) does not affect the expression of the ob gene in Zucker obese rats. | 0-139 | 0 | 139 | Short-term @SUBJECT$ @PREDICAT$ estrone @OBJECT$ in liposomes (Merlin-2) does not affect the expression of the ob gene in Zucker obese rats. |
Counterfact | preserve | 996-1002 | 996-1002 | T92 | effect | INTERACTS_WITH | 996 | 1,002 | preserve | 982-988 | 982-988 | T78 | oleate | Lipid | 982 | 988 | preserve | 1010-1016 | 1010-1016 | T80 | leptin | AminoAcidPeptideOrProtein | 1,010 | 1,016 | A19 | The fact that estrone oleate had no effect on the leptin levels or expression in obese rats, in contrast with the marked inhibition observed in the lean suggests that the functionality of the leptin receptor is essential for estrone oleate inhibition of the ob gene. | 954-1244 | 954 | 1,244 | The fact that estrone @SUBJECT$ had no @PREDICAT$ on the @OBJECT$ levels or expression in obese rats, in contrast with the marked inhibition observed in the lean suggests that the functionality of the leptin receptor is essential for estrone oleate inhibition of the ob gene. |
Fact | preserve | 128-138 | 134-138 | T14 | obese rats | PROCESS_OF | 128 | 138 | preserve | 128-133 | 128-133 | T10 | obese | DiseaseOrSyndrome | 128 | 133 | preserve | 121-138 | 134-138 | T11 | Zucker obese rats | Mammal | 121 | 138 | A20 | Short-term treatment with estrone oleate in liposomes (Merlin-2) does not affect the expression of the ob gene in Zucker obese rats. | 0-139 | 0 | 139 | Short-term treatment with estrone oleate in liposomes (Merlin-2) does not affect the expression of the ob gene in @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 274-278 | 274-278 | T17 | with | PROCESS_OF | 274 | 278 | preserve | 279-312 | 302-312 | T13 | acute myocardial infarction | DiseaseOrSyndrome | 279 | 312 | preserve | 265-273 | 265-273 | T12 | patients | PatientOrDisabledGroup | 265 | 273 | A2 | BACKGROUND: In this study we have evaluated the prognostic power of noninvasive markers of coronary artery reperfusion in patients with acute myocardial infarction who were treated with intravenous streptokinase. | 137-361 | 137 | 361 | BACKGROUND: In this study we have evaluated the prognostic power of noninvasive markers of coronary artery reperfusion in @OBJECT$ @PREDICAT$ @SUBJECT$ who were treated with intravenous streptokinase. |
Fact | preserve | 405-409 | 405-409 | T39 | with | PROCESS_OF | 405 | 409 | preserve | 410-437 | 427-437 | T22 | acute myocardial infarction | DiseaseOrSyndrome | 410 | 437 | preserve | 396-404 | 396-404 | T21 | patients | PatientOrDisabledGroup | 396 | 404 | A3 | METHODS: In 967 consecutive patients with acute myocardial infarction who were treated within 6 hours of symptoms, we analyzed the prognostic power of resolution of chest pain and ST-segment elevation >50% at 90 minutes, abrupt creatine kinase rise before 12 hours, and T-wave inversion in infarct-related electrocardiographic leads within the first 24 hours after thrombolysis. | 362-770 | 362 | 770 | METHODS: In 967 consecutive @OBJECT$ @PREDICAT$ @SUBJECT$ who were treated within 6 hours of symptoms, we analyzed the prognostic power of resolution of chest pain and ST-segment elevation >50% at 90 minutes, abrupt creatine kinase rise before 12 hours, and T-wave inversion in infarct-related electrocardiographic leads within the first 24 hours after thrombolysis. |
Fact | preserve | 262-264 | 262-264 | T16 | in | TREATS | 262 | 264 | preserve | 234-261 | 250-261 | T11 | coronary artery reperfusion | TherapeuticOrPreventiveProcedure | 234 | 261 | preserve | 279-312 | 302-312 | T13 | acute myocardial infarction | DiseaseOrSyndrome | 279 | 312 | A4 | BACKGROUND: In this study we have evaluated the prognostic power of noninvasive markers of coronary artery reperfusion in patients with acute myocardial infarction who were treated with intravenous streptokinase. | 137-361 | 137 | 361 | BACKGROUND: In this study we have evaluated the prognostic power of noninvasive markers of @SUBJECT$ @PREDICAT$ patients with @OBJECT$ who were treated with intravenous streptokinase. |
Fact | preserve | 86-90 | 86-90 | T6 | with | PROCESS_OF | 86 | 90 | preserve | 123-135 | 123-135 | T5 | thrombolysis | ClinicalAttribute | 123 | 135 | preserve | 71-79 | 71-79 | T3 | patients | PatientOrDisabledGroup | 71 | 79 | A5 | Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis. | 0-136 | 0 | 136 | Bedside markers of coronary artery patency and short-term prognosis of @OBJECT$ @PREDICAT$ acute myocardial infarction and @SUBJECT$ . |
Fact | preserve | 86-90 | 86-90 | T6 | with | PROCESS_OF | 86 | 90 | preserve | 91-118 | 108-118 | T4 | acute myocardial infarction | DiseaseOrSyndrome | 91 | 118 | preserve | 71-79 | 71-79 | T3 | patients | PatientOrDisabledGroup | 71 | 79 | A6 | Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis. | 0-136 | 0 | 136 | Bedside markers of coronary artery patency and short-term prognosis of @OBJECT$ @PREDICAT$ @SUBJECT$ and thrombolysis. |
Fact | preserve | 262-264 | 262-264 | T16 | in | TREATS | 262 | 264 | preserve | 234-261 | 250-261 | T11 | coronary artery reperfusion | TherapeuticOrPreventiveProcedure | 234 | 261 | preserve | 265-273 | 265-273 | T12 | patients | PatientOrDisabledGroup | 265 | 273 | A7 | BACKGROUND: In this study we have evaluated the prognostic power of noninvasive markers of coronary artery reperfusion in patients with acute myocardial infarction who were treated with intravenous streptokinase. | 137-361 | 137 | 361 | BACKGROUND: In this study we have evaluated the prognostic power of noninvasive markers of @SUBJECT$ @PREDICAT$ @OBJECT$ with acute myocardial infarction who were treated with intravenous streptokinase. |
Fact | preserve | 1749-1780 | 1776-1780 | T99 | salmeterol is quite a safe drug | ISA | 1,749 | 1,780 | preserve | 1749-1759 | 1749-1759 | T94 | salmeterol | OrganicChemical | 1,749 | 1,759 | preserve | 1776-1780 | 1776-1780 | T95 | drug | PharmacologicSubstance | 1,776 | 1,780 | A1 | CONCLUSIONS: As no cardiac side effects were detected, it could be concluded that salmeterol is quite a safe drug for use in childhood asthma treatment. | 1661-1825 | 1,661 | 1,825 | CONCLUSIONS: As no cardiac side effects were detected, it could be concluded that @SUBJECT$ @PREDICAT$ @OBJECT$ for use in childhood asthma treatment. |
Fact | preserve | 1815-1824 | 1815-1824 | T100 | treatment | TREATS | 1,815 | 1,824 | preserve | 1776-1780 | 1776-1780 | T95 | drug | PharmacologicSubstance | 1,776 | 1,780 | preserve | 1798-1814 | 1808-1814 | T97 | childhood asthma | DiseaseOrSyndrome | 1,798 | 1,814 | A2 | CONCLUSIONS: As no cardiac side effects were detected, it could be concluded that salmeterol is quite a safe drug for use in childhood asthma treatment. | 1661-1825 | 1,661 | 1,825 | CONCLUSIONS: As no cardiac side effects were detected, it could be concluded that salmeterol is quite a safe @SUBJECT$ for use in @OBJECT$ @PREDICAT$ . |
Fact | preserve | 250-252 | 250-252 | T24 | in | PROCESS_OF | 250 | 252 | preserve | 223-235 | 223-235 | T19 | side-effects | PathologicFunction | 223 | 235 | preserve | 269-275 | 269-275 | T22 | adults | AgeGroup | 269 | 275 | A3 | There are some reports about the cardiac side-effects of salmeterol in asthmatic adults. | 182-276 | 182 | 276 | There are some reports about the cardiac @SUBJECT$ of salmeterol @PREDICAT$ asthmatic @OBJECT$ . |
Fact | preserve | 496-500 | 496-500 | T44 | with | USES | 496 | 500 | preserve | 393-401 | 393-401 | T32 | children | AgeGroup | 393 | 401 | preserve | 503-516 | 510-516 | T38 | spacer device | MedicalDevice | 503 | 516 | A4 | METHODS: Seventeen children with moderate asthma (aged between 6 and 13 years, mean 8.76 years) received salmeterol with a spacer device (Volumatic 200 micrograms daily, b.i.d.) for 3 weeks. | 374-576 | 374 | 576 | METHODS: Seventeen @SUBJECT$ with moderate asthma (aged between 6 and 13 years, mean 8.76 years) received salmeterol @PREDICAT$ a @OBJECT$ (Volumatic 200 micrograms daily, b.i.d.) for 3 weeks. |
Fact | preserve | 402-406 | 402-406 | T43 | with | PROCESS_OF | 402 | 406 | preserve | 407-422 | 416-422 | T33 | moderate asthma | Finding | 407 | 422 | preserve | 393-401 | 393-401 | T32 | children | AgeGroup | 393 | 401 | A5 | METHODS: Seventeen children with moderate asthma (aged between 6 and 13 years, mean 8.76 years) received salmeterol with a spacer device (Volumatic 200 micrograms daily, b.i.d.) for 3 weeks. | 374-576 | 374 | 576 | METHODS: Seventeen @OBJECT$ @PREDICAT$ @SUBJECT$ (aged between 6 and 13 years, mean 8.76 years) received salmeterol with a spacer device (Volumatic 200 micrograms daily, b.i.d.) for 3 weeks. |
Fact | preserve | 62-64 | 62-64 | T11 | in | PROCESS_OF | 62 | 64 | preserve | 8-20 | 13-20 | T2 | side effects | PathologicFunction | 8 | 20 | preserve | 81-89 | 81-89 | T9 | children | AgeGroup | 81 | 89 | A6 | Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children. | 0-90 | 0 | 90 | Cardiac @SUBJECT$ of long-acting beta-2 agonist salmeterol @PREDICAT$ asthmatic @OBJECT$ . |
Fact | preserve | 65-89 | 81-89 | T10 | asthmatic children | PROCESS_OF | 65 | 89 | preserve | 65-74 | 65-74 | T8 | asthmatic | DiseaseOrSyndrome | 65 | 74 | preserve | 81-89 | 81-89 | T9 | children | AgeGroup | 81 | 89 | A7 | Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children. | 0-90 | 0 | 90 | Cardiac side effects of long-acting beta-2 agonist salmeterol in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 259-275 | 269-275 | T23 | asthmatic adults | PROCESS_OF | 259 | 275 | preserve | 259-268 | 259-268 | T21 | asthmatic | DiseaseOrSyndrome | 259 | 268 | preserve | 269-275 | 269-275 | T22 | adults | AgeGroup | 269 | 275 | A8 | There are some reports about the cardiac side-effects of salmeterol in asthmatic adults. | 182-276 | 182 | 276 | There are some reports about the cardiac side-effects of salmeterol in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Possible | preserve | 1749-1780 | 1776-1780 | T101 | salmeterol is quite a safe drug | TREATS | 1,749 | 1,780 | preserve | 1749-1759 | 1749-1759 | T94 | salmeterol | OrganicChemical | 1,749 | 1,759 | preserve | 1798-1814 | 1808-1814 | T97 | childhood asthma | DiseaseOrSyndrome | 1,798 | 1,814 | A9 | CONCLUSIONS: As no cardiac side effects were detected, it could be concluded that salmeterol is quite a safe drug for use in childhood asthma treatment. | 1661-1825 | 1,661 | 1,825 | CONCLUSIONS: As no cardiac side effects were detected, it could be concluded that @SUBJECT$ @PREDICAT$ for use in @OBJECT$ treatment. |
Fact | preserve | 361-363 | 361-363 | T30 | in | PROCESS_OF | 361 | 363 | preserve | 328-340 | 333-340 | T27 | side effects | PathologicFunction | 328 | 340 | preserve | 364-372 | 364-372 | T29 | children | AgeGroup | 364 | 372 | A10 | The aim of this study was to determine the cardiac side effects of salmeterol in children. | 277-373 | 277 | 373 | The aim of this study was to determine the cardiac @SUBJECT$ of salmeterol @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1163-1188 | 1177-1188 | T64 | retina venous obstruction | LOCATION_OF | 1,163 | 1,188 | preserve | 1163-1169 | 1163-1169 | T61 | retina | BodyPartOrganOrOrganComponent | 1,163 | 1,169 | preserve | 1155-1188 | 1177-1188 | T62 | central retina venous obstruction | PathologicFunction | 1,155 | 1,188 | A1 | DISCUSSION: The few cases described would offer an explanation of the low prevalence of cilioretinal arteries and the more frequent association with central retina venous obstruction which can mask arterial occlusion. | 993-1229 | 993 | 1,229 | DISCUSSION: The few cases described would offer an explanation of the low prevalence of cilioretinal arteries and the more frequent association with @OBJECT$ @SUBJECT$ @PREDICAT$ which can mask arterial occlusion. |
Fact | preserve | 796-806 | 796-806 | T43 | controlled | TREATS | 796 | 806 | preserve | 823-830 | 823-830 | T42 | regimen | ResearchActivity | 823 | 830 | preserve | 759-771 | 759-771 | T39 | hypertension | DiseaseOrSyndrome | 759 | 771 | A2 | RESULTS: Systemic examinations revealed severe hypertension (240/130) rapidly controlled with a two-drug regimen. | 712-831 | 712 | 831 | RESULTS: Systemic examinations revealed severe @OBJECT$ (240/130) rapidly @PREDICAT$ with a two-drug @SUBJECT$ . |
Fact | preserve | 418-420 | 418-420 | T24 | in | LOCATION_OF | 418 | 420 | preserve | 425-434 | 431-434 | T22 | right eye | BodyPartOrganOrOrganComponent | 425 | 434 | preserve | 399-417 | 413-417 | T21 | sudden visual loss | SignOrSymptom | 399 | 417 | A3 | CASE REPORT AND METHOD: A 56-year-old man had sudden visual loss in the right eye estimated at 3/10 P10. | 347-463 | 347 | 463 | CASE REPORT AND METHOD: A 56-year-old man had @OBJECT$ @PREDICAT$ the @SUBJECT$ estimated at 3/10 P10. |
Fact | preserve | 818-830 | 823-830 | T44 | drug regimen | USES | 818 | 830 | preserve | 823-830 | 823-830 | T42 | regimen | ResearchActivity | 823 | 830 | preserve | 818-822 | 818-822 | T41 | drug | PharmacologicSubstance | 818 | 822 | A4 | RESULTS: Systemic examinations revealed severe hypertension (240/130) rapidly controlled with a two-drug regimen. | 712-831 | 712 | 831 | RESULTS: Systemic examinations revealed severe hypertension (240/130) rapidly controlled with a two- @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1988-1992 | 1988-1992 | T102 | with | PROCESS_OF | 1,988 | 1,992 | preserve | 1993-2006 | 1999-2006 | T101 | heart failure | DiseaseOrSyndrome | 1,993 | 2,006 | preserve | 1979-1987 | 1979-1987 | T100 | patients | PatientOrDisabledGroup | 1,979 | 1,987 | A1 | Ongoing large scale clinical trials may confirm the mounting evidence, from numerous clinical studies, that these agents may prolong survival in patients with heart failure. | 1822-2007 | 1,822 | 2,007 | Ongoing large scale clinical trials may confirm the mounting evidence, from numerous clinical studies, that these agents may prolong survival in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 501-508 | 501-508 | T41 | relieve | TREATS | 501 | 508 | preserve | 462-469 | 462-469 | T29 | therapy | TherapeuticOrPreventiveProcedure | 462 | 469 | preserve | 512-520 | 512-520 | T30 | symptoms | SignOrSymptom | 512 | 520 | A2 | Short term goals of therapy are directed towards the relieve of symptoms that can be commonly managed by the use of vasodilators, diuretics, digoxin, in order to obtain an improvement in myocardial functional capacity and quality of life of patients. | 442-710 | 442 | 710 | Short term goals of @SUBJECT$ are directed towards the @PREDICAT$ of @OBJECT$ that can be commonly managed by the use of vasodilators, diuretics, digoxin, in order to obtain an improvement in myocardial functional capacity and quality of life of patients. |
Fact | preserve | 1711-1719 | 1711-1719 | T91 | improves | AFFECTS | 1,711 | 1,719 | preserve | 1629-1636 | 1629-1636 | T81 | therapy | TherapeuticOrPreventiveProcedure | 1,629 | 1,636 | preserve | 1720-1745 | 1737-1745 | T86 | left ventricular function | OrganOrTissueFunction | 1,720 | 1,745 | A3 | Accumulating clinical evidence indicates that beta blocker therapy, particularly with third generation beta-blocking agents, not only improves left ventricular function but also may reduce and reverse pathological remodeling in the heart. | 1563-1821 | 1,563 | 1,821 | Accumulating clinical evidence indicates that beta blocker @SUBJECT$ , particularly with third generation beta-blocking agents, not only @PREDICAT$ @OBJECT$ but also may reduce and reverse pathological remodeling in the heart. |
Fact | preserve | 1616-1636 | 1629-1636 | T90 | beta blocker therapy | USES | 1,616 | 1,636 | preserve | 1629-1636 | 1629-1636 | T81 | therapy | TherapeuticOrPreventiveProcedure | 1,629 | 1,636 | preserve | 1616-1628 | 1621-1628 | T80 | beta blocker | PharmacologicSubstance | 1,616 | 1,628 | A4 | Accumulating clinical evidence indicates that beta blocker therapy, particularly with third generation beta-blocking agents, not only improves left ventricular function but also may reduce and reverse pathological remodeling in the heart. | 1563-1821 | 1,563 | 1,821 | Accumulating clinical evidence indicates that @OBJECT$ @PREDICAT$ @SUBJECT$ , particularly with third generation beta-blocking agents, not only improves left ventricular function but also may reduce and reverse pathological remodeling in the heart. |
Fact | preserve | 297-304 | 297-304 | T21 | results | CAUSES | 297 | 304 | preserve | 322-358 | 350-358 | T19 | left ventricular pump function | OrganOrTissueFunction | 322 | 358 | preserve | 228-254 | 245-254 | T14 | peripheric perfusion | Finding | 228 | 254 | A5 | Heart failure, still nowadays an important cause of morbidity and mortality in many countries, is a complex of symptoms related to inadequate peripheric perfusion and often to the retention of fluid, that results from an impaired left ventricular pump function. | 80-359 | 80 | 359 | Heart failure, still nowadays an important cause of morbidity and mortality in many countries, is a complex of symptoms related to inadequate @OBJECT$ and often to the retention of fluid, that @PREDICAT$ from an impaired @SUBJECT$ . |
Possible | preserve | 1534-1544 | 1534-1544 | T78 | management | TREATS | 1,534 | 1,544 | preserve | 1484-1510 | 1504-1510 | T75 | beta-blocking agents | PharmacologicSubstance | 1,484 | 1,510 | preserve | 1548-1561 | 1554-1561 | T77 | heart failure | DiseaseOrSyndrome | 1,548 | 1,561 | A8 | This new conceptual model has first led to the widespread introduction of angiotensin converting inhibitors in clinical practice; then, the evidence that sympathetic activation might play an important role in the progression of heart failure, led the investigators to propose that beta-blocking agents might be useful in the management of heart failure. | 1185-1562 | 1,185 | 1,562 | This new conceptual model has first led to the widespread introduction of angiotensin converting inhibitors in clinical practice; then, the evidence that sympathetic activation might play an important role in the progression of heart failure, led the investigators to propose that @SUBJECT$ might be useful in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 690-692 | 690-692 | T44 | in | TREATS | 690 | 692 | preserve | 663-683 | 671-683 | T40 | dietary intervention | TherapeuticOrPreventiveProcedure | 663 | 683 | preserve | 699-707 | 699-707 | T42 | children | AgeGroup | 699 | 707 | A2 | The primary purpose of this study was to evaluate changes in protein utilization in response to sequential addition of an exercise program to dietary intervention in obese children. | 514-708 | 514 | 708 | The primary purpose of this study was to evaluate changes in protein utilization in response to sequential addition of an exercise program to @SUBJECT$ @PREDICAT$ obese @OBJECT$ . |
Fact | preserve | 690-692 | 690-692 | T44 | in | TREATS | 690 | 692 | preserve | 663-683 | 671-683 | T40 | dietary intervention | TherapeuticOrPreventiveProcedure | 663 | 683 | preserve | 693-698 | 693-698 | T41 | obese | DiseaseOrSyndrome | 693 | 698 | A3 | The primary purpose of this study was to evaluate changes in protein utilization in response to sequential addition of an exercise program to dietary intervention in obese children. | 514-708 | 514 | 708 | The primary purpose of this study was to evaluate changes in protein utilization in response to sequential addition of an exercise program to @SUBJECT$ @PREDICAT$ @OBJECT$ children. |
Fact | preserve | 168-188 | 180-188 | T22 | obese children | PROCESS_OF | 168 | 188 | preserve | 168-173 | 168-173 | T13 | obese | DiseaseOrSyndrome | 168 | 173 | preserve | 180-188 | 180-188 | T14 | children | AgeGroup | 180 | 188 | A4 | PURPOSE: Hypocaloric therapy may adversely affect protein utilization in obese children given that metabolic reactions involving protein, a nutrient essential for growth, are energy-dependent. | 95-299 | 95 | 299 | PURPOSE: Hypocaloric therapy may adversely affect protein utilization in @SUBJECT$ @PREDICAT$ @OBJECT$ given that metabolic reactions involving protein, a nutrient essential for growth, are energy-dependent. |
Fact | preserve | 1842-1856 | 1848-1856 | T107 | obese children | PROCESS_OF | 1,842 | 1,856 | preserve | 1842-1847 | 1842-1847 | T102 | obese | DiseaseOrSyndrome | 1,842 | 1,847 | preserve | 1848-1856 | 1848-1856 | T103 | children | AgeGroup | 1,848 | 1,856 | A5 | CONCLUSIONS: These results suggest that exercise offers metabolic benefits for obese children during diet-induced weight loss. | 1757-1895 | 1,757 | 1,895 | CONCLUSIONS: These results suggest that exercise offers metabolic benefits for @SUBJECT$ @PREDICAT$ @OBJECT$ during diet-induced weight loss. |
Fact | preserve | 693-707 | 699-707 | T43 | obese children | PROCESS_OF | 693 | 707 | preserve | 693-698 | 693-698 | T41 | obese | DiseaseOrSyndrome | 693 | 698 | preserve | 699-707 | 699-707 | T42 | children | AgeGroup | 699 | 707 | A6 | The primary purpose of this study was to evaluate changes in protein utilization in response to sequential addition of an exercise program to dietary intervention in obese children. | 514-708 | 514 | 708 | The primary purpose of this study was to evaluate changes in protein utilization in response to sequential addition of an exercise program to dietary intervention in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 73-93 | 85-93 | T7 | obese children | PROCESS_OF | 73 | 93 | preserve | 73-78 | 73-78 | T5 | obese | DiseaseOrSyndrome | 73 | 78 | preserve | 85-93 | 85-93 | T6 | children | AgeGroup | 85 | 93 | A10 | Effects of exercise combined with diet therapy on protein utilization in obese children. | 0-94 | 0 | 94 | Effects of exercise combined with diet therapy on protein utilization in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Probable | preserve | 1601-1605 | 1601-1605 | T88 | risk | PREDISPOSES | 1,601 | 1,605 | preserve | 1571-1580 | 1571-1580 | T82 | tamoxifen | OrganicChemical | 1,571 | 1,580 | preserve | 1609-1630 | 1621-1630 | T84 | endometrial carcinoma | NeoplasticProcess | 1,609 | 1,630 | A1 | CONCLUSION: It was concluded that positive endometrial findings and endometrial thickness were due to continuous unopposed tamoxifen treatment and our findings support the hypothesis that tamoxifen increases the risk of endometrial carcinoma and premalignant changes. | 1371-1656 | 1,371 | 1,656 | CONCLUSION: It was concluded that positive endometrial findings and endometrial thickness were due to continuous unopposed tamoxifen treatment and our findings support the hypothesis that @SUBJECT$ increases the @PREDICAT$ of @OBJECT$ and premalignant changes. |
Fact | preserve | 1334-1359 | 1350-1359 | T70 | tamoxifen treatment | ISA | 1,334 | 1,359 | preserve | 1334-1343 | 1334-1343 | T68 | tamoxifen | OrganicChemical | 1,334 | 1,343 | preserve | 1350-1359 | 1350-1359 | T69 | treatment | TherapeuticOrPreventiveProcedure | 1,350 | 1,359 | A2 | A significant relation was noticed between endometrial thickness and duration of tamoxifen treatment (p=0.025). | 1247-1370 | 1,247 | 1,370 | A significant relation was noticed between endometrial thickness and duration of @SUBJECT$ @PREDICAT$ @OBJECT$ (p=0.025). |
Fact | preserve | 1334-1359 | 1350-1359 | T71 | tamoxifen treatment | USES | 1,334 | 1,359 | preserve | 1350-1359 | 1350-1359 | T69 | treatment | TherapeuticOrPreventiveProcedure | 1,350 | 1,359 | preserve | 1334-1343 | 1334-1343 | T68 | tamoxifen | OrganicChemical | 1,334 | 1,343 | A3 | A significant relation was noticed between endometrial thickness and duration of tamoxifen treatment (p=0.025). | 1247-1370 | 1,247 | 1,370 | A significant relation was noticed between endometrial thickness and duration of @OBJECT$ @PREDICAT$ @SUBJECT$ (p=0.025). |
Fact | preserve | 1500-1525 | 1516-1525 | T86 | tamoxifen treatment | ISA | 1,500 | 1,525 | preserve | 1500-1509 | 1500-1509 | T78 | tamoxifen | OrganicChemical | 1,500 | 1,509 | preserve | 1516-1525 | 1516-1525 | T79 | treatment | TherapeuticOrPreventiveProcedure | 1,516 | 1,525 | A4 | CONCLUSION: It was concluded that positive endometrial findings and endometrial thickness were due to continuous unopposed tamoxifen treatment and our findings support the hypothesis that tamoxifen increases the risk of endometrial carcinoma and premalignant changes. | 1371-1656 | 1,371 | 1,656 | CONCLUSION: It was concluded that positive endometrial findings and endometrial thickness were due to continuous unopposed @SUBJECT$ @PREDICAT$ @OBJECT$ and our findings support the hypothesis that tamoxifen increases the risk of endometrial carcinoma and premalignant changes. |
Uncommitted | preserve | 127-134 | 127-134 | T14 | effects | AFFECTS | 127 | 134 | preserve | 138-147 | 138-147 | T10 | tamoxifen | OrganicChemical | 138 | 147 | preserve | 155-166 | 155-166 | T11 | endometrium | BodyPartOrganOrOrganComponent | 155 | 166 | A5 | OBJECTIVE: To investigate the effects of tamoxifen on the endometrium in postmenopausal breast cancer patients. | 97-214 | 97 | 214 | OBJECTIVE: To investigate the @PREDICAT$ of @SUBJECT$ on the @OBJECT$ in postmenopausal breast cancer patients. |
Fact | preserve | 67-74 | 67-74 | T7 | treated | TREATS | 67 | 74 | preserve | 86-95 | 86-95 | T5 | tamoxifen | OrganicChemical | 86 | 95 | preserve | 58-66 | 58-66 | T4 | patients | PatientOrDisabledGroup | 58 | 66 | A8 | Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. | 0-96 | 0 | 96 | Endometrial pathology of 104 postmenopausal breast cancer @OBJECT$ @PREDICAT$ with @SUBJECT$ . |
Fact | preserve | 1500-1525 | 1516-1525 | T87 | tamoxifen treatment | USES | 1,500 | 1,525 | preserve | 1516-1525 | 1516-1525 | T79 | treatment | TherapeuticOrPreventiveProcedure | 1,516 | 1,525 | preserve | 1500-1509 | 1500-1509 | T78 | tamoxifen | OrganicChemical | 1,500 | 1,509 | A9 | CONCLUSION: It was concluded that positive endometrial findings and endometrial thickness were due to continuous unopposed tamoxifen treatment and our findings support the hypothesis that tamoxifen increases the risk of endometrial carcinoma and premalignant changes. | 1371-1656 | 1,371 | 1,656 | CONCLUSION: It was concluded that positive endometrial findings and endometrial thickness were due to continuous unopposed @OBJECT$ @PREDICAT$ @SUBJECT$ and our findings support the hypothesis that tamoxifen increases the risk of endometrial carcinoma and premalignant changes. |
Fact | preserve | 44-66 | 58-66 | T6 | breast cancer patients | PROCESS_OF | 44 | 66 | preserve | 44-57 | 51-57 | T3 | breast cancer | NeoplasticProcess | 44 | 57 | preserve | 58-66 | 58-66 | T4 | patients | PatientOrDisabledGroup | 58 | 66 | A11 | Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. | 0-96 | 0 | 96 | Endometrial pathology of 104 postmenopausal @SUBJECT$ @PREDICAT$ @OBJECT$ treated with tamoxifen. |
Fact | preserve | 67-74 | 67-74 | T7 | treated | TREATS | 67 | 74 | preserve | 86-95 | 86-95 | T5 | tamoxifen | OrganicChemical | 86 | 95 | preserve | 44-57 | 51-57 | T3 | breast cancer | NeoplasticProcess | 44 | 57 | A12 | Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. | 0-96 | 0 | 96 | Endometrial pathology of 104 postmenopausal @OBJECT$ patients @PREDICAT$ with @SUBJECT$ . |
Fact | preserve | 191-213 | 205-213 | T15 | breast cancer patients | PROCESS_OF | 191 | 213 | preserve | 191-204 | 198-204 | T12 | breast cancer | NeoplasticProcess | 191 | 204 | preserve | 205-213 | 205-213 | T13 | patients | PatientOrDisabledGroup | 205 | 213 | A14 | OBJECTIVE: To investigate the effects of tamoxifen on the endometrium in postmenopausal breast cancer patients. | 97-214 | 97 | 214 | OBJECTIVE: To investigate the effects of tamoxifen on the endometrium in postmenopausal @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1221-1236 | 1228-1236 | T101 | stroke patients | PROCESS_OF | 1,221 | 1,236 | preserve | 1221-1227 | 1221-1227 | T88 | stroke | DiseaseOrSyndrome | 1,221 | 1,227 | preserve | 1228-1236 | 1228-1236 | T89 | patients | PatientOrDisabledGroup | 1,228 | 1,236 | A1 | WMC in stroke patients are often associated with small-vessel disease and lead to a higher risk of death, and poor cardiac and neurological outcome. | 1214-1375 | 1,214 | 1,375 | WMC in @SUBJECT$ @PREDICAT$ @OBJECT$ are often associated with small-vessel disease and lead to a higher risk of death, and poor cardiac and neurological outcome. |
Fact | preserve | 792-796 | 792-796 | T67 | with | PROCESS_OF | 792 | 796 | preserve | 797-813 | 805-813 | T56 | lacunar infarcts | DiseaseOrSyndrome | 797 | 813 | preserve | 783-791 | 783-791 | T55 | patients | PatientOrDisabledGroup | 783 | 791 | A2 | WMC are more frequent in patients with lacunar infarcts, deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral amyloid angiopathy. | 752-982 | 752 | 982 | WMC are more frequent in @OBJECT$ @PREDICAT$ @SUBJECT$ , deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral amyloid angiopathy. |
Fact | preserve | 894-898 | 894-898 | T68 | with | PROCESS_OF | 894 | 898 | preserve | 911-919 | 911-919 | T64 | infarcts | PathologicFunction | 911 | 919 | preserve | 783-791 | 783-791 | T55 | patients | PatientOrDisabledGroup | 783 | 791 | A3 | WMC are more frequent in patients with lacunar infarcts, deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral amyloid angiopathy. | 752-982 | 752 | 982 | WMC are more frequent in @OBJECT$ with lacunar infarcts, deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy @PREDICAT$ subcortical @SUBJECT$ and leukoencephalopathy and cerebral amyloid angiopathy. |
Fact | preserve | 894-898 | 894-898 | T68 | with | PROCESS_OF | 894 | 898 | preserve | 930-949 | 930-949 | T65 | leukoencephalopathy | DiseaseOrSyndrome | 930 | 949 | preserve | 783-791 | 783-791 | T55 | patients | PatientOrDisabledGroup | 783 | 791 | A4 | WMC are more frequent in patients with lacunar infarcts, deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral amyloid angiopathy. | 752-982 | 752 | 982 | WMC are more frequent in @OBJECT$ with lacunar infarcts, deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy @PREDICAT$ subcortical infarcts and @SUBJECT$ and cerebral amyloid angiopathy. |
Fact | preserve | 728-732 | 728-732 | T50 | with | PROCESS_OF | 728 | 732 | preserve | 733-750 | 742-750 | T47 | vascular dementia | DiseaseOrSyndrome | 733 | 750 | preserve | 719-727 | 719-727 | T46 | patients | PatientOrDisabledGroup | 719 | 727 | A6 | WMC, as defined radiologically, are present in up to 44% of patients with stroke or TIA and in 50% of patients with vascular dementia. | 611-751 | 611 | 751 | WMC, as defined radiologically, are present in up to 44% of patients with stroke or TIA and in 50% of @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 680-684 | 680-684 | T48 | with | PROCESS_OF | 680 | 684 | preserve | 701-704 | 701-704 | T45 | TIA | DiseaseOrSyndrome | 701 | 704 | preserve | 671-679 | 671-679 | T43 | patients | PatientOrDisabledGroup | 671 | 679 | A7 | WMC, as defined radiologically, are present in up to 44% of patients with stroke or TIA and in 50% of patients with vascular dementia. | 611-751 | 611 | 751 | WMC, as defined radiologically, are present in up to 44% of @OBJECT$ @PREDICAT$ stroke or @SUBJECT$ and in 50% of patients with vascular dementia. |
Fact | preserve | 175-190 | 182-190 | T15 | stroke patients | PROCESS_OF | 175 | 190 | preserve | 175-181 | 175-181 | T13 | stroke | DiseaseOrSyndrome | 175 | 181 | preserve | 182-190 | 182-190 | T14 | patients | PatientOrDisabledGroup | 182 | 190 | A8 | White matter changes (WMC), detected by imaging techniques, are frequent in stroke patients. | 93-191 | 93 | 191 | White matter changes (WMC), detected by imaging techniques, are frequent in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1119-1136 | 1128-1136 | T86 | cerebral bleeding | LOCATION_OF | 1,119 | 1,136 | preserve | 1119-1127 | 1119-1127 | T81 | cerebral | BodyPartOrganOrOrganComponent | 1,119 | 1,127 | preserve | 1128-1136 | 1128-1136 | T82 | bleeding | Finding | 1,128 | 1,136 | A9 | After an acute ischemic stroke, WMC are associated with a higher risk of death or dependency, recurrent stroke of any type, cerebral bleeding under anticoagulation, myocardial infarction, and poststroke dementia. | 983-1213 | 983 | 1,213 | After an acute ischemic stroke, WMC are associated with a higher risk of death or dependency, recurrent stroke of any type, @SUBJECT$ @PREDICAT$ @OBJECT$ under anticoagulation, myocardial infarction, and poststroke dementia. |
Fact | preserve | 24-39 | 31-39 | T4 | stroke patients | PROCESS_OF | 24 | 39 | preserve | 24-30 | 24-30 | T2 | stroke | DiseaseOrSyndrome | 24 | 30 | preserve | 31-39 | 31-39 | T3 | patients | PatientOrDisabledGroup | 31 | 39 | A10 | White matter changes in stroke patients. | 0-40 | 0 | 40 | White matter changes in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 894-898 | 894-898 | T68 | with | PROCESS_OF | 894 | 898 | preserve | 954-981 | 971-981 | T66 | cerebral amyloid angiopathy | DiseaseOrSyndrome | 954 | 981 | preserve | 783-791 | 783-791 | T55 | patients | PatientOrDisabledGroup | 783 | 791 | A13 | WMC are more frequent in patients with lacunar infarcts, deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral amyloid angiopathy. | 752-982 | 752 | 982 | WMC are more frequent in @OBJECT$ with lacunar infarcts, deep intracerebral hemorrhages, cerebral autosomal dominant arteriopathy @PREDICAT$ subcortical infarcts and leukoencephalopathy and @SUBJECT$ . |
Fact | preserve | 680-684 | 680-684 | T48 | with | PROCESS_OF | 680 | 684 | preserve | 691-697 | 691-697 | T44 | stroke | DiseaseOrSyndrome | 691 | 697 | preserve | 671-679 | 671-679 | T43 | patients | PatientOrDisabledGroup | 671 | 679 | A14 | WMC, as defined radiologically, are present in up to 44% of patients with stroke or TIA and in 50% of patients with vascular dementia. | 611-751 | 611 | 751 | WMC, as defined radiologically, are present in up to 44% of @OBJECT$ @PREDICAT$ @SUBJECT$ or TIA and in 50% of patients with vascular dementia. |
Fact | preserve | 539-545 | 539-542 | T63 | due to | CAUSES | 539 | 545 | preserve | 551-558 | 551-558 | T48 | allergy | PathologicFunction | 551 | 558 | preserve | 532-538 | 532-538 | T46 | asthma | DiseaseOrSyndrome | 532 | 538 | A2 | METHOD: Thirty-six patients with rhinitis and asthma due to mite allergy were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. | 486-813 | 486 | 813 | METHOD: Thirty-six patients with rhinitis and @OBJECT$ @PREDICAT$ mite @SUBJECT$ were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. |
Fact | preserve | 459-465 | 459-462 | T36 | due to | CAUSES | 459 | 465 | preserve | 477-484 | 477-484 | T29 | allergy | PathologicFunction | 477 | 484 | preserve | 452-458 | 452-458 | T27 | asthma | DiseaseOrSyndrome | 452 | 458 | A3 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 patients with rhinitis and asthma due to mite allergy. | 248-485 | 248 | 485 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 patients with rhinitis and @OBJECT$ @PREDICAT$ mite @SUBJECT$ . |
Fact | preserve | 2212-2216 | 2212-2216 | T147 | with | PROCESS_OF | 2,212 | 2,216 | preserve | 2217-2240 | 2232-2240 | T145 | allergic rhinitis | DiseaseOrSyndrome | 2,217 | 2,240 | preserve | 2203-2211 | 2203-2211 | T144 | patients | PatientOrDisabledGroup | 2,203 | 2,211 | A6 | CONCLUSION: Sublingual immunotherapy may be effective in patients with allergic rhinitis. | 2146-2241 | 2,146 | 2,241 | CONCLUSION: Sublingual immunotherapy may be effective in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 985-998 | 990-998 | T79 | IgG4 antibody | ISA | 985 | 998 | preserve | 985-989 | 985-989 | T76 | IgG4 | AminoAcidPeptideOrProtein | 985 | 989 | preserve | 990-998 | 990-998 | T77 | antibody | AminoAcidPeptideOrProtein | 990 | 998 | A7 | Assessment of clinical and immunologic efficacy included symptom and medication scores, methacholine provocation tests, skin prick tests, and specific IgE and IgG4 antibody concentrations. | 814-1014 | 814 | 1,014 | Assessment of clinical and immunologic efficacy included symptom and medication scores, methacholine provocation tests, skin prick tests, and specific IgE and @SUBJECT$ @PREDICAT$ @OBJECT$ concentrations. |
Fact | preserve | 434-438 | 434-438 | T33 | with | PROCESS_OF | 434 | 438 | preserve | 452-458 | 452-458 | T27 | asthma | DiseaseOrSyndrome | 452 | 458 | preserve | 425-433 | 425-433 | T25 | patients | PatientOrDisabledGroup | 425 | 433 | A10 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 patients with rhinitis and asthma due to mite allergy. | 248-485 | 248 | 485 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 @OBJECT$ @PREDICAT$ rhinitis and @SUBJECT$ due to mite allergy. |
Fact | preserve | 72-74 | 72-74 | T9 | in | TREATS | 72 | 74 | preserve | 58-71 | 58-71 | T2 | immunotherapy | TherapeuticOrPreventiveProcedure | 58 | 71 | preserve | 110-118 | 110-118 | T6 | rhinitis | DiseaseOrSyndrome | 110 | 118 | A11 | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. | 0-158 | 0 | 158 | Comparison of the efficacy of subcutaneous and sublingual @SUBJECT$ @PREDICAT$ mite-sensitive patients with @OBJECT$ and asthma--a placebo controlled study. |
Fact | preserve | 349-356 | 349-356 | T30 | compare | compared_with | 349 | 356 | preserve | 328-341 | 328-341 | T21 | immunotherapy | TherapeuticOrPreventiveProcedure | 328 | 341 | preserve | 374-406 | 393-406 | T23 | subcutaneous immunotherapy | TherapeuticOrPreventiveProcedure | 374 | 406 | A13 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 patients with rhinitis and asthma due to mite allergy. | 248-485 | 248 | 485 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual @SUBJECT$ and to @PREDICAT$ the results with @OBJECT$ and placebo in 36 patients with rhinitis and asthma due to mite allergy. |
Probable | preserve | 2200-2202 | 2200-2202 | T146 | in | TREATS | 2,200 | 2,202 | preserve | 2169-2182 | 2169-2182 | T142 | immunotherapy | TherapeuticOrPreventiveProcedure | 2,169 | 2,182 | preserve | 2217-2240 | 2232-2240 | T145 | allergic rhinitis | DiseaseOrSyndrome | 2,217 | 2,240 | A14 | CONCLUSION: Sublingual immunotherapy may be effective in patients with allergic rhinitis. | 2146-2241 | 2,146 | 2,241 | CONCLUSION: Sublingual @SUBJECT$ may be effective @PREDICAT$ patients with @OBJECT$ . |
Probable | preserve | 2288-2291 | 2288-2291 | T156 | for | TREATS | 2,288 | 2,291 | preserve | 2280-2287 | 2280-2287 | T151 | therapy | TherapeuticOrPreventiveProcedure | 2,280 | 2,287 | preserve | 2301-2310 | 2301-2310 | T153 | asthmatic | DiseaseOrSyndrome | 2,301 | 2,310 | A15 | Further, we believe it is a potential therapy for allergic asthmatic patients. | 2242-2326 | 2,242 | 2,326 | Further, we believe it is a potential @SUBJECT$ @PREDICAT$ allergic @OBJECT$ patients. |
Fact | preserve | 195-199 | 195-199 | T17 | with | USES | 195 | 199 | preserve | 187-194 | 187-194 | T14 | therapy | TherapeuticOrPreventiveProcedure | 187 | 194 | preserve | 211-228 | 220-228 | T15 | allergen extracts | IndicatorReagentOrDiagnosticAid | 211 | 228 | A16 | BACKGROUND: The efficacy of therapy with sublingual allergen extracts is unproven. | 159-247 | 159 | 247 | BACKGROUND: The efficacy of @SUBJECT$ @PREDICAT$ sublingual @OBJECT$ is unproven. |
Probable | preserve | 2288-2291 | 2288-2291 | T156 | for | TREATS | 2,288 | 2,291 | preserve | 2280-2287 | 2280-2287 | T151 | therapy | TherapeuticOrPreventiveProcedure | 2,280 | 2,287 | preserve | 2317-2325 | 2317-2325 | T154 | patients | PatientOrDisabledGroup | 2,317 | 2,325 | A17 | Further, we believe it is a potential therapy for allergic asthmatic patients. | 2242-2326 | 2,242 | 2,326 | Further, we believe it is a potential @SUBJECT$ @PREDICAT$ allergic asthmatic @OBJECT$ . |
Fact | preserve | 1121-1128 | 1121-1128 | T96 | treated | TREATS | 1,121 | 1,128 | preserve | 1151-1164 | 1151-1164 | T88 | immunotherapy | TherapeuticOrPreventiveProcedure | 1,151 | 1,164 | preserve | 1112-1120 | 1112-1120 | T87 | Patients | PatientOrDisabledGroup | 1,112 | 1,120 | A18 | Patients treated with sublingual immunotherapy had decreased rhinitis symptoms (P < .01) but no change in asthma scores. | 1112-1244 | 1,112 | 1,244 | @OBJECT$ @PREDICAT$ with sublingual @SUBJECT$ had decreased rhinitis symptoms (P < .01) but no change in asthma scores. |
Fact | preserve | 105-109 | 105-109 | T10 | with | PROCESS_OF | 105 | 109 | preserve | 110-118 | 110-118 | T6 | rhinitis | DiseaseOrSyndrome | 110 | 118 | preserve | 96-104 | 96-104 | T5 | patients | PatientOrDisabledGroup | 96 | 104 | A19 | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. | 0-158 | 0 | 158 | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive @OBJECT$ @PREDICAT$ @SUBJECT$ and asthma--a placebo controlled study. |
Probable | preserve | 2200-2202 | 2200-2202 | T146 | in | TREATS | 2,200 | 2,202 | preserve | 2169-2182 | 2169-2182 | T142 | immunotherapy | TherapeuticOrPreventiveProcedure | 2,169 | 2,182 | preserve | 2203-2211 | 2203-2211 | T144 | patients | PatientOrDisabledGroup | 2,203 | 2,211 | A20 | CONCLUSION: Sublingual immunotherapy may be effective in patients with allergic rhinitis. | 2146-2241 | 2,146 | 2,241 | CONCLUSION: Sublingual @SUBJECT$ may be effective @PREDICAT$ @OBJECT$ with allergic rhinitis. |
Fact | preserve | 539-545 | 539-542 | T63 | due to | CAUSES | 539 | 545 | preserve | 551-558 | 551-558 | T48 | allergy | PathologicFunction | 551 | 558 | preserve | 519-527 | 519-527 | T45 | rhinitis | DiseaseOrSyndrome | 519 | 527 | A21 | METHOD: Thirty-six patients with rhinitis and asthma due to mite allergy were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. | 486-813 | 486 | 813 | METHOD: Thirty-six patients with @OBJECT$ and asthma @PREDICAT$ mite @SUBJECT$ were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. |
Fact | preserve | 514-518 | 514-518 | T60 | with | PROCESS_OF | 514 | 518 | preserve | 532-538 | 532-538 | T46 | asthma | DiseaseOrSyndrome | 532 | 538 | preserve | 505-513 | 505-513 | T44 | patients | PatientOrDisabledGroup | 505 | 513 | A22 | METHOD: Thirty-six patients with rhinitis and asthma due to mite allergy were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. | 486-813 | 486 | 813 | METHOD: Thirty-six @OBJECT$ @PREDICAT$ rhinitis and @SUBJECT$ due to mite allergy were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. |
Fact | preserve | 459-465 | 459-462 | T36 | due to | CAUSES | 459 | 465 | preserve | 477-484 | 477-484 | T29 | allergy | PathologicFunction | 477 | 484 | preserve | 439-447 | 439-447 | T26 | rhinitis | DiseaseOrSyndrome | 439 | 447 | A24 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 patients with rhinitis and asthma due to mite allergy. | 248-485 | 248 | 485 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 patients with @OBJECT$ and asthma @PREDICAT$ mite @SUBJECT$ . |
Fact | preserve | 72-74 | 72-74 | T9 | in | TREATS | 72 | 74 | preserve | 58-71 | 58-71 | T2 | immunotherapy | TherapeuticOrPreventiveProcedure | 58 | 71 | preserve | 96-104 | 96-104 | T5 | patients | PatientOrDisabledGroup | 96 | 104 | A25 | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. | 0-158 | 0 | 158 | Comparison of the efficacy of subcutaneous and sublingual @SUBJECT$ @PREDICAT$ mite-sensitive @OBJECT$ with rhinitis and asthma--a placebo controlled study. |
Fact | preserve | 105-109 | 105-109 | T10 | with | PROCESS_OF | 105 | 109 | preserve | 123-129 | 123-129 | T7 | asthma | DiseaseOrSyndrome | 123 | 129 | preserve | 96-104 | 96-104 | T5 | patients | PatientOrDisabledGroup | 96 | 104 | A27 | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. | 0-158 | 0 | 158 | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive @OBJECT$ @PREDICAT$ rhinitis and @SUBJECT$ --a placebo controlled study. |
Fact | preserve | 1051-1054 | 1051-1054 | T85 | for | TREATS | 1,051 | 1,054 | preserve | 1024-1050 | 1037-1050 | T81 | Subcutaneous immunotherapy | TherapeuticOrPreventiveProcedure | 1,024 | 1,050 | preserve | 1066-1074 | 1066-1074 | T82 | rhinitis | DiseaseOrSyndrome | 1,066 | 1,074 | A28 | RESULTS: Subcutaneous immunotherapy for both rhinitis and asthma was clinically effective. | 1015-1111 | 1,015 | 1,111 | RESULTS: @SUBJECT$ @PREDICAT$ both @OBJECT$ and asthma was clinically effective. |
Fact | preserve | 1051-1054 | 1051-1054 | T85 | for | TREATS | 1,051 | 1,054 | preserve | 1024-1050 | 1037-1050 | T81 | Subcutaneous immunotherapy | TherapeuticOrPreventiveProcedure | 1,024 | 1,050 | preserve | 1079-1085 | 1079-1085 | T83 | asthma | DiseaseOrSyndrome | 1,079 | 1,085 | A29 | RESULTS: Subcutaneous immunotherapy for both rhinitis and asthma was clinically effective. | 1015-1111 | 1,015 | 1,111 | RESULTS: @SUBJECT$ @PREDICAT$ both rhinitis and @OBJECT$ was clinically effective. |
Fact | preserve | 434-438 | 434-438 | T33 | with | PROCESS_OF | 434 | 438 | preserve | 439-447 | 439-447 | T26 | rhinitis | DiseaseOrSyndrome | 439 | 447 | preserve | 425-433 | 425-433 | T25 | patients | PatientOrDisabledGroup | 425 | 433 | A30 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 patients with rhinitis and asthma due to mite allergy. | 248-485 | 248 | 485 | OBJECTIVE: To evaluate the clinical and immunologic outcome of sublingual immunotherapy and to compare the results with subcutaneous immunotherapy and placebo in 36 @OBJECT$ @PREDICAT$ @SUBJECT$ and asthma due to mite allergy. |
Fact | preserve | 2301-2325 | 2317-2325 | T155 | asthmatic patients | PROCESS_OF | 2,301 | 2,325 | preserve | 2301-2310 | 2301-2310 | T153 | asthmatic | DiseaseOrSyndrome | 2,301 | 2,310 | preserve | 2317-2325 | 2317-2325 | T154 | patients | PatientOrDisabledGroup | 2,317 | 2,325 | A31 | Further, we believe it is a potential therapy for allergic asthmatic patients. | 2242-2326 | 2,242 | 2,326 | Further, we believe it is a potential therapy for allergic @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 72-74 | 72-74 | T9 | in | TREATS | 72 | 74 | preserve | 58-71 | 58-71 | T2 | immunotherapy | TherapeuticOrPreventiveProcedure | 58 | 71 | preserve | 123-129 | 123-129 | T7 | asthma | DiseaseOrSyndrome | 123 | 129 | A32 | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. | 0-158 | 0 | 158 | Comparison of the efficacy of subcutaneous and sublingual @SUBJECT$ @PREDICAT$ mite-sensitive patients with rhinitis and @OBJECT$ --a placebo controlled study. |
Fact | preserve | 514-518 | 514-518 | T60 | with | PROCESS_OF | 514 | 518 | preserve | 519-527 | 519-527 | T45 | rhinitis | DiseaseOrSyndrome | 519 | 527 | preserve | 505-513 | 505-513 | T44 | patients | PatientOrDisabledGroup | 505 | 513 | A33 | METHOD: Thirty-six patients with rhinitis and asthma due to mite allergy were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. | 486-813 | 486 | 813 | METHOD: Thirty-six @OBJECT$ @PREDICAT$ @SUBJECT$ and asthma due to mite allergy were randomly divided into three groups in order to receive subcutaneous injections with allergenic extracts, sublingual drops with solutions of purified standardized allergen preparations, or sublingual placebo for a period of 1 year. |
Fact | preserve | 1326-1335 | 1326-1335 | T68 | treatment | TREATS | 1,326 | 1,335 | preserve | 1155-1165 | 1155-1165 | T54 | Etanercept | AminoAcidPeptideOrProtein | 1,155 | 1,165 | preserve | 1345-1353 | 1345-1353 | T64 | patients | PatientOrDisabledGroup | 1,345 | 1,353 | A1 | Etanercept, a bioengineered soluble receptor fusion protein that blocks tumor necrosis factor activity, is the first compound in this class to be approved for treatment of patients with refractory rheumatoid arthritis. | 1155-1391 | 1,155 | 1,391 | @SUBJECT$ , a bioengineered soluble receptor fusion protein that blocks tumor necrosis factor activity, is the first compound in this class to be approved for @PREDICAT$ of @OBJECT$ with refractory rheumatoid arthritis. |
Fact | preserve | 1354-1358 | 1354-1358 | T69 | with | PROCESS_OF | 1,354 | 1,358 | preserve | 1370-1390 | 1381-1390 | T66 | rheumatoid arthritis | DiseaseOrSyndrome | 1,370 | 1,390 | preserve | 1345-1353 | 1345-1353 | T64 | patients | PatientOrDisabledGroup | 1,345 | 1,353 | A2 | Etanercept, a bioengineered soluble receptor fusion protein that blocks tumor necrosis factor activity, is the first compound in this class to be approved for treatment of patients with refractory rheumatoid arthritis. | 1155-1391 | 1,155 | 1,391 | Etanercept, a bioengineered soluble receptor fusion protein that blocks tumor necrosis factor activity, is the first compound in this class to be approved for treatment of @OBJECT$ @PREDICAT$ refractory @SUBJECT$ . |
Probable | preserve | 1446-1452 | 1446-1452 | T82 | reduce | PREVENTS | 1,446 | 1,452 | preserve | 1431-1441 | 1431-1441 | T72 | etanercept | AminoAcidPeptideOrProtein | 1,431 | 1,441 | preserve | 1453-1460 | 1453-1460 | T73 | disease | DiseaseOrSyndrome | 1,453 | 1,460 | A3 | Therapeutic trials indicate that etanercept can reduce disease activity with relatively few drug-related adverse effects, thus helping persons with rheumatoid arthritis return to more normal, healthy lives. | 1392-1616 | 1,392 | 1,616 | Therapeutic trials indicate that @SUBJECT$ can @PREDICAT$ @OBJECT$ activity with relatively few drug-related adverse effects, thus helping persons with rheumatoid arthritis return to more normal, healthy lives. |
Fact | preserve | 774-783 | 774-783 | T42 | Treatment | TREATS | 774 | 783 | preserve | 872-908 | 903-908 | T37 | nonsteroidal anti-inflammatory drugs | PharmacologicSubstance | 872 | 908 | preserve | 787-807 | 798-807 | T35 | rheumatoid arthritis | DiseaseOrSyndrome | 787 | 807 | A4 | Treatment of rheumatoid arthritis typically involves disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, and low-dose corticosteroids--often used in combination. | 774-973 | 774 | 973 | @PREDICAT$ of @OBJECT$ typically involves disease-modifying antirheumatic drugs, @SUBJECT$ , and low-dose corticosteroids--often used in combination. |